Eli Lilly Stock News & Updates
[WKN: 858560 | Symbol: LLY]
Eli Lilly: Cost Advantages in Obesity Therapy Secure Reimbursement Prospects for the Healthcare System
Zepbound reduces monthly costs for patients aged 55 and older by up to $607. Reduced hospital stays...
Eli Lilly: GLP-1 Market Leader Grows by 48% in Record Quarter - Stock Near All-Time High!
The second quarter impresses with a revenue growth of 48%. Mounjaro and Zepbound set a revenue record...
Eli Lilly: Capacity Expansion and Huge Demand for GLP-1 Medications Shape Q2 - Strategic Acquisitions to Secure Further Growth!
Eli Lilly significantly benefits from the massive demand for Mounjaro and Zepbound, which mimic saturation...
US Markets in Geopolitical Stranglehold – Trump threatens Iran with massive military retaliation – Trump imposes new global tariffs – Brent crude oil breaks $100 mark – Intel celebrates a spectacular comeback thanks to AI boom – Lockheed Martin shines with record orders – SAP impresses with strong cloud growth – Oracle secures billion-dollar military contract – Eli Lilly ignites next level in weight loss race
After the latest trading day on Thursday, July 23, 2026, the US stock markets presented themselves in...
Eli Lilly: Direct Attack on Johnson & Johnson in the Market for Depression Therapies
Eli Lilly diversifies its business model beyond weight loss and diabetes medications with an aggressive...
US Markets with Slight Losses – Ceasefire between the US and Iran – Devastating Earthquake in Venezuela Claims Thousands of Lives – GE Vernova Sold Out by 2029 – Eli Lilly on the Brink of Billion-Dollar Windfall through Medicare – Storage Crisis Forces Microsoft to Raise Prices – Alphabet Reduces AI Capacities for Meta – Elon Musk Tests Grok 4.5 at SpaceX and Tesla – Nvidia and Firmus Technologies Forge Billion Dollar Alliance for AI Infrastructure
After the latest trading day on Friday, June 26, 2026, the US markets showed a slight consolidation phase....
Medicare Covers Eli Lilly’s GLP-1 Medications Starting July! Morgan Stanley Raises Market Volume to $190 Billion!
Milestone in the USA: Starting July 2026, millions of seniors will gain access to GLP-1 medications...
Eli Lilly Strengthens GLP-1 Leadership Claim – Foundayo Surpasses Oral Semaglutide!
Eli Lilly is driving its growth through global dominance in the incretin drug market with Mounjaro...
Middle East conflict continues to weigh on DAX at the start of the week - Chemical stocks pressured after Goldman Sachs study - DEUTZ rises significantly after Warburg Buy rating - CTS Eventim under pressure following Exane downgrade - Eli Lilly surprises with positive study data on Retatrutide!
The DAX is showing somewhat larger declines in early trading due to the recent escalation in the Middle...
Eli Lilly Impresses with Study Data on Foundayo and Retatrutide – Stock Rises Over 4%!
The FDA approval for Foundayo as the first GLP-1 pill without fasting requirements is also convincing...
Escalation in the Middle East shakes the markets – US labor market report shatters forecasts and fuels interest rate fears – Alphabet closes $30 billion deal with SpaceX – Nvidia solidifies storage alliance with SK Hynix – Marvell Technology and Flex join the S&P 500 – Eli Lilly shines with new data on obesity drug – Lululemon in free fall after catastrophic outlook
After the recent trading day on Friday, June 5, 2026, US markets presented themselves in a deep red sell-off...